Vanguard Portfolio Management Reports 5.0% Stake in Neurocrine Biosciences

Overview

On October 30, 2026, Vanguard Portfolio Management filed a Schedule 13G with the SEC disclosing beneficial ownership of 5,083,540 shares of Neurocrine Biosciences Inc (NASDAQ: NBIX) Common Stock as of September 30, 2026.

Key Filing Details

• Reporting Entity: Vanguard Portfolio Management (CIK: 0002100121)
• Issuer: Neurocrine Biosciences Inc (CIK: 0000914475)
• Class of Security: Common Stock (CUSIP: 64125C109)
• Filing Rule: Rule 13d-1(b) (filed in the ordinary course of business by an institutional investment adviser)
• Aggregate Beneficial Ownership: 5,083,540 shares
• Ownership Percentage: 5.0%

Voting and Dispositive Authority

• Sole Voting Power: 23,504 shares
• Shared Voting Power: 0 shares
• Sole Dispositive Power: 5,083,540 shares
• Shared Dispositive Power: 0 shares

Analysis & Market Implications

• Investment Nature: As a Schedule 13G filing under Rule 13d-1(b), this position is held passively in the ordinary course of business and not for the purpose of influencing or changing control of the issuer.
• Significance: Passive institutional ownership filings at the 5% threshold are routine rebalancing or asset allocation adjustments by large index and mutual fund managers like Vanguard, representing low market trading impact.